Navigation Links
5(S)-HETE-d8, Deuterium Conjugated/Tagged from Cayman Chemical

Products5(S)-HETE-d8, Deuterium Conjugated/Tagged from Cayman Chemical
Company Cayman Chemical
Item 5(S)-HETE-d8, Deuterium Conjugated/Tagged
Price $374.00
Description 5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry.
Info Cayman ChemicalCayman Chemical
Cayman Chemical Company
1180 East Ellsworth Road
Ann Arbor, Michigan 48108
Customer Service: (800) 364-9897
Fax Number: (734) 971-3640
Web Site: http://www.caymanchem.com/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. 15(S)-HETE-d8, Deuterium Conjugated/Tagged from Cayman Chemical
2. 5(S)-HETE-d8, Deuterium Conjugated/Tagged from Cayman Chemical
3. 20-HETE-d6, Deuterium Conjugated/Tagged from Cayman Chemical
4. 20-HETE-d6, Deuterium Conjugated/Tagged from Cayman Chemical
5. 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical
6. 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical
7. 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical
8. 13(S)-HODE-d4, Deuterium Conjugated/Tagged from Cayman Chemical
9. 13(S)-HODE-d4, Deuterium Conjugated/Tagged from Cayman Chemical
10. 12(S)-HETE-d8, Deuterium Conjugated/Tagged from Cayman Chemical
11. 12(S)-HETE-d8, Deuterium Conjugated/Tagged from Cayman Chemical
15(S)-HETE-d8 is used as an internal standard for the quantification of 15(S)-HETE by stable isotope dilution mass spectrometry....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products:
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Researchers at Georgetown University Medical Center have discovered ... on genes that can push stem cells embedded in a ... build blood vessels to link up to the body,s blood ... published in the July 16 online issue of PLoS ...
... Although sickle cell disease is a single-gene disorder, its ... July 14 by the Proceedings of the National ... and the Dana Farber Cancer Institute (DFCI), in collaboration ... five gene variants that could potentially be helpful in ...
... 15, 2008 A new book from the Soil Science Society of ... living world of soil. Soil! Get the Inside Scoop explores how ... the air we breathe, the water we drink, the houses we ... healthy plants and food production. Written for children age 9 to ...
Cached Biology News:Vitamin A pushes breast cancer to form blood vessel cells 2Vitamin A pushes breast cancer to form blood vessel cells 3Gaining ground on sickle cell disease 2Gaining ground on sickle cell disease 3
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... May 21, 2015 W. R. ... manufacturing facility in Worms, Germany has received good ... subsidiary of the International Pharmaceutical Excipient Council (IPEC) ... that produce its SYLOID® FP brand of pharmaceutical ... certification, following the Curtis Bay, Maryland (USA) and ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7